Clinical Trial Update: Tenofovir to Prevent HBV Reactivation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on using tenofovir to prevent hepatitis B reactivation in patients with hematologic malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Tenofovir (Tenofovir)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hepatitis B, Lymphoma | Phase 3 | Status: UNKNOWN